Project Grant R21AI185965
Award Date
8/12/24
Completion Date
7/31/26
Dollars Obligated
$212K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Austin, TX 78759, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $466,500.00 to support the development of a rapid and ultrasensitive aptamer-based detection technology for Treponema pallidum, the causative agent of syphilis. The goal is to create an inexpensive, point-of-care diagnostic test that can accurately diagnose syphilis in both adults and congenital cases, enabling...
This $233,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop rapid point-of-care assays for detecting antibiotic resistance in the bacteria that causes syphilis, Treponema pallidum. The key products to be delivered under this 2-year grant include: A multiplexed, point-of-care loop-mediated isothermal amplification (LAMP) assay to detect single nucleotide...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $260,760 Project Grant to the University of Victoria (Advancement Services) to develop a direct diagnostic test for infectious and congenital syphilis. The proposed test aims to exhibit high sensitivity and specificity, differentiate active versus past infections, distinguish syphilis from yaws, enable accurate disease staging, and be adaptable to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an integrated multiplexed diagnostic assay for the rapid detection and semi-quantification of treponemal and nontreponemal antibodies associated with syphilis infection. The $698,349 award, spanning from February 2025 to January 2029, will support the creation of an electrochemical sensing platform...
This $499,151 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel diagnostic test for syphilis. The project aims to create an immuno-PCR diagnostic platform that can detect peptidoglycan fragments shed by the syphilis-causing bacterium Treponema pallidum, allowing for early-stage disease detection. The award provides funding over a 2-year...
This federal Project Grant award, valued at $205,000 and made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to identify novel biomarkers for the diagnosis of syphilis in pregnancy and assessment of treatment response. The key products or services to be delivered through this funding include: Analyzing longitudinally collected samples from a prospective cohort of pregnant patients diagnosed...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $246,000.00 to The University of Texas Southwestern Medical Center to conduct research on optimizing molecular polymerase chain reaction (PCR) testing for the diagnosis of congenital syphilis. The key objectives are to determine whether PCR can detect Treponema pallidum DNA in neonates exposed to maternal...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $163,698 to Magic Lifescience, Inc. to develop a novel point-of-care molecular diagnostic assay for syphilis detection. The goal is to create a multiplexed genital ulcer disease (GUD) panel test that can rapidly diagnose syphilis and other pathogens using giant magnetoresistive (GMR) biosensors. This new...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $264,750 to the University of Washington to develop and validate a tiling amplicon sequencing approach for recovering complete Treponema pallidum genomes from diverse clinical specimens. The goal is to improve the analytical sensitivity and ease of workflow for T. pallidum genome recovery, enabling more effective...
This Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $1,250,000 in funding to Prompt Diagnostics, Inc. to develop an automated, point-of-care diagnostic platform for detecting infections caused by Treponema pallidum, the bacterium that causes syphilis. The platform will combine rapid plasma reagin (RPR) and antibody tests into a multiplexed cartridge, enabling comprehensive diagnosis within...